Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]
PHASE2CompletedINTERVENTIONAL
Enrollment
26
Participants
Timeline
Start Date
October 17, 2018
Primary Completion Date
January 15, 2021
Study Completion Date
January 15, 2021
Conditions
SCLC
Interventions
DRUG
AZD6738
AZD6738 160mg QD
DRUG
Olaparib
Olaparib 300mg BID
Trial Locations (1)
Unknown
Samsung Medical Center, Seoul
All Listed Sponsors
lead
Samsung Medical Center
OTHER
NCT03428607 - Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | Biotech Hunter | Biotech Hunter